Truist Financial Has Lowered Expectations for IQVIA (NYSE:IQV) Stock Price

IQVIA (NYSE:IQV) had its price target dropped by analysts at Truist Financial from $265.00 to $261.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Truist Financial’s price objective points to a potential upside of 30.29% from the company’s previous close.

IQV has been the topic of a number of other research reports. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Wednesday. Redburn Atlantic started coverage on shares of IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price target on the stock. Deutsche Bank Aktiengesellschaft reduced their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Robert W. Baird reduced their price target on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating on the stock in a research report on Wednesday. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $257.60.

IQVIA Stock Performance

Shares of NYSE:IQV traded down $0.74 on Thursday, reaching $200.33. 432,280 shares of the company’s stock were exchanged, compared to its average volume of 1,182,924. The company has a fifty day moving average of $213.40 and a 200-day moving average of $224.61. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a market capitalization of $36.36 billion, a price-to-earnings ratio of 26.29, a PEG ratio of 2.08 and a beta of 1.49. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

Hedge Funds Weigh In On IQVIA

A number of hedge funds have recently bought and sold shares of the company. Simplify Asset Management Inc. grew its holdings in IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the period. Raymond James & Associates grew its holdings in IQVIA by 0.7% in the second quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after purchasing an additional 5,417 shares during the period. Versor Investments LP acquired a new stake in IQVIA in the third quarter worth $1,328,000. Gradient Investments LLC grew its holdings in IQVIA by 15.6% in the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock worth $9,600,000 after purchasing an additional 6,134 shares during the period. Finally, CIBC Asset Management Inc grew its holdings in IQVIA by 3.3% in the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock worth $62,501,000 after purchasing an additional 8,490 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.